Skip to content
ContentLora

    Tip: press / anywhere to search.

    product

    Ivonescimab

    Also known as SMT112, AK112

    Ivonescimab is an investigational bispecific antibody that blocks both PD-1 and VEGF, licensed by Summit Therapeutics from Akeso and approved in China since May 2024.[1][2][3] The FDA set a decision date of 14 November 2026 for its use with chemotherapy in EGFR-mutated non-squamous lung cancer after targeted therapy; as of Summit's 4 November update it was not approved in the US or Europe.[4][5] The application rests on the HARMONi trial, which met its progression-free survival endpoint but did not show a statistically significant overall survival benefit.[6][7]

    Editor reviewedStrict sourcingUpdated Wiki11 claims · 100% primaryCancer immunotherapy, Health and medicine
    Key facts

    Ivonescimab is a bispecific antibody that combines an immunotherapy effect, blocking PD-1, with an anti-angiogenesis effect, blocking VEGF, in one molecule.[1] Summit Therapeutics licensed it from the Chinese drugmaker Akeso in January 2023.[2] It has been approved in China since May 2024, but as of 4 November 2026 it was not approved by any regulator in Summit’s territories, including the US and Europe.[3][5]

    This page is not medical advice. Anyone weighing cancer treatment should talk to their oncologist.

    The US application

    In January 2026 the FDA accepted Summit’s application for ivonescimab plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy. The FDA set a goal date of 14 November 2026.[4] In its 4 November results, Summit described the application as pending and said it would announce the outcome and hold a call after the FDA acted.[8] For background on the process, see how FDA drug approval works.

    What the HARMONi trial showed

    The application rests on the global phase 3 HARMONi trial. It met its primary endpoint of progression-free survival, and Summit called it the first global phase 3 study of an immunotherapy-based regimen to show a statistically significant progression-free survival benefit in this setting.[6] Overall survival, the trial’s other primary endpoint, showed a positive trend that was not statistically significant.[7] Summit disclosed that the FDA had said a statistically significant overall survival benefit is necessary to support approval in this setting, so the decision turns on that gap.[7]

    Trials run by Akeso in China

    Akeso has run several phase 3 trials in China. In HARMONi-2, ivonescimab alone extended median overall survival to 30.8 months, against 22.6 months with pembrolizumab, in first-line PD-L1-positive non-small cell lung cancer (hazard ratio 0.73).[9] In squamous lung cancer, the HARMONi-6 trial reported a 34% lower risk of death with ivonescimab plus chemotherapy than with tislelizumab plus chemotherapy.[10] In October 2026 the HARMONi-GI1 trial in biliary tract cancer reported better overall survival with ivonescimab plus chemotherapy than with durvalumab plus chemotherapy (hazard ratio 0.75).[11] These were single-country trials, and the US application rests on HARMONi.[11][6]

    Where it fits

    Ivonescimab belongs to the wider field of cancer immunotherapy. It targets the same PD-1 pathway as immune-checkpoint-inhibitors, and adds VEGF blockade.[1] For the disease itself, see lung cancer explained.

    What to watch

    The next milestone is the FDA’s action on the application, due by 14 November 2026, which Summit has said it will announce in a press release.[4][8]

    Immune checkpoint inhibitors

    Checkpoint inhibitors such as pembrolizumab release immune brakes like PD-1 and CTLA-4. How they work, who responds, side effects and 2026 approvals.

    More in Immunotherapy

    Questions readers ask

    What is ivonescimab?

    An antibody with two arms. One blocks PD-1, the target of immunotherapy drugs such as pembrolizumab; the other blocks VEGF, which tumours use to grow blood vessels. Summit Therapeutics calls it SMT112 and Akeso calls it AK112.[1]

    Is ivonescimab approved in the US?

    Not as of Summit's 4 November 2026 update. The FDA's goal date for a decision on the lung cancer application was 14 November 2026, and Summit said it would announce the outcome after the FDA acted.[5][4][8]

    Where is ivonescimab already approved?

    In China, where it was first approved in May 2024.[3]

    Why is the overall survival result important?

    In the HARMONi trial, overall survival showed a positive trend that was not statistically significant. Summit disclosed that the FDA had said a statistically significant overall survival benefit is necessary to support approval in this setting.[7]

    How did ivonescimab compare with pembrolizumab?

    In Akeso's HARMONi-2 trial in China, ivonescimab alone extended median overall survival to 30.8 months versus 22.6 months with pembrolizumab in first-line PD-L1-positive lung cancer.[9]

    Sources

    · 11 claims from 2 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Summit Therapeutics describes ivonescimab as an investigational bispecific antibody that combines PD-1 blockade (an immunotherapy effect) with VEGF blockade (an anti-angiogenesis effect) in a single molecule. It is called SMT112 in Summit's licence territories and AK112 elsewhere. confirmedas of 2026-11-04

    2. [2]

      Summit Therapeutics in-licensed ivonescimab from the Chinese drugmaker Akeso in January 2023. confirmedas of 2026-11-04

    3. [3]

      Ivonescimab was first approved for marketing in China in May 2024. confirmedas of 2026-11-04

    4. [4]

      In January 2026 the FDA accepted Summit's Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy, with a PDUFA goal date of 14 November 2026. confirmedas of 2026-11-04

    5. [5]

      As of 4 November 2026, Summit said ivonescimab was not approved by any regulator in its licence territories, which include the United States and Europe. confirmedas of 2026-11-04

    6. [6]

      The application rests on the global phase 3 HARMONi trial, which met its progression-free survival primary endpoint; Summit called it the first global phase 3 study of an immunotherapy-based regimen to show a statistically significant progression-free survival improvement in this setting. confirmedas of 2026-11-04

    7. [7]

      In HARMONi's primary overall survival analysis, ivonescimab plus chemotherapy showed a positive trend that was not statistically significant, and Summit disclosed that the FDA had said a statistically significant overall survival benefit is necessary to support approval in this setting. confirmedas of 2026-11-04

    8. [8]

      In its 4 November 2026 results, Summit described the application as pending and said it would issue a press release and hold a call after the FDA acted. confirmedas of 2026-11-04

    9. [9]

      Akeso reported in September 2026 that its PD-1 x VEGF bispecific ivonescimab extended median overall survival to 30.8 months versus 22.6 months with pembrolizumab in first-line PD-L1-positive non-small cell lung cancer in the HARMONi-2 trial (hazard ratio 0.73). confirmedas of 2026-09-13

    10. [10]

      Akeso reported that in the 532-patient phase 3 HARMONi-6 trial in squamous non-small cell lung cancer, ivonescimab plus chemotherapy reduced the risk of death by 34% versus tislelizumab plus chemotherapy (hazard ratio 0.66); results were presented at the ASCO 2026 plenary. confirmedas of 2026-05-31

    11. [11]

      In October 2026 Akeso's phase 3 HARMONi-GI1 study in biliary tract cancer, conducted in China, reported that ivonescimab plus chemotherapy improved overall survival compared with durvalumab plus chemotherapy (hazard ratio 0.75). confirmedas of 2026-11-04

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 21, 2026.

    Cite this page

    "Ivonescimab." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/ivonescimab

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.